I. Tanin

Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study

A. Hagenbeek, G. Salles, A. López-Guillermo, 2010 .